Skip to content

Marrow Therapeutics

Developer of antibody-drug conjugate treatments for sickle cell disease and beta thalassemia.

Marrow Therapeutics is a biotech & life sciences company based in Watertown, US. It has raised $173 million in disclosed funding. Its latest round was a Series B of $173 million in November 2026.

Overview

No overview yet. It is written from sources once there are enough of them.

Funding

Total disclosed: $173M across 1 round. Computed only from sourced rounds.

  • Nov 17 · Series B

    Led by Scion Life Sciences, Venbio Partners, OrbiMed · with RTW Investments, +7

    Biotech & Life Sciences1 source

Investors

Questions and answers

What does Marrow Therapeutics do?

Developer of antibody-drug conjugate treatments for sickle cell disease and beta thalassemia.

How much has Marrow Therapeutics raised?

Marrow Therapeutics has raised $173 million in disclosed funding across 1 round tracked by OSH.

Who has invested in Marrow Therapeutics?

Investors in Marrow Therapeutics include Scion Life Sciences, Venbio Partners, OrbiMed, RTW Investments, Surveyor Capital and 6 more.

When and where was Marrow Therapeutics founded?

Marrow Therapeutics and is based in Watertown, US.

Sources

  1. 1.Sickle Cell Drug: Marrow Raises $173 Million Without Releasing Anemia or Selectivity Data — techtimes.com, Nov 17, 2026

Public sources — Collected from public sources, not yet cross-checked.Last verified Nov 20, 2026